Skip to content
  • Home
  • About IPPI
    • Our Purpose
    • Team & Affiliates
    • Advisory Board
    • Funding & Support
    • Institutional Partners
    • History
  • Blog
    • IPPI Blog
    • List of All Blog Posts
  • Writing
    • Amicus Briefs
    • Letters, Comments, & Testimony
    • Policy Writing
    • Scholarship
  • Events
    • All Events
    • Conflicts Calendar
    • IPPI 2026 Winter Institute
      • 2026 Agenda
    • WIPO-U.S. Summer School on IP
      • 2026 Agenda
  • Edison Fellowship
  • Contact
IPPI: The IP Policy Institute

IPPI: The IP Policy Institute

The University of Akron School of Law

Domestic Manufacturing as a Discretionary Consideration: Domestic Industry at the PTAB?

Posted on: May 18, 2026Innovation , Patent Law , Patents

By Michael Doane IPPI Scholar & Assistant Professor of Law, The University of Akron School of Law Since the beginning, the second Trump Administration indicated that the promotion of domestic […]

If AI Can Pirate the Internet, Why Can’t You?

Posted on: May 11, 2026May 18, 2026Artificial Intelligence , Copyright , Copyright Licensing , Fair Use , Innovation

By David Atkinson David Atkinson is a Postdoctoral Fellow at Georgetown University Law Center and a 2026-2027 IPPI Edison Fellow. The legal argument that could either protect copyright forever — […]

Most-Favored-Nation (MFN) Drug Pricing: You Can’t Import European Prices Without Importing European Tradeoffs

Posted on: May 4, 2026May 13, 2026Healthcare , Innovation , Patent Law , Patents , Pharma

By Dr. Gabriela Lenarczyk Dr. Lenarczyk is a 2024-2025 Edison Fellow. This blog post is in partial  fulfillment of obligations for the Thomas Edison Innovation Law and Policy Fellowship. Recently resurfaced […]

IPPI Cautions that Pharmaceutical Tariffs Would Harm Patients and U.S. Innovation Leadership

Posted on: May 9, 2025May 13, 2026Biotech , Healthcare , Innovation , International Law , IPPI News , Patent Law , Patents , Pharma

IPPI has submitted formal comments to the U.S. Department of Commerce regarding its Section 232 investigation of pharmaceutical imports, cautioning against imposing tariffs on medicines and their ingredients. In our […]

[Archived Post] Panel on “SEP Current & Proposed Regulations” at C-IP2’s 2024 Annual Fall Conference

Posted on: November 20, 2024May 13, 2026Conferences , High Tech Industry , Innovation , Patent Law , Patents , Software Patent

By Keith Mallinson It was my pleasure to participate in a panel session on “SEP Current & Proposed Regulations” last month at the George Mason University Antonin Scalia Law School […]

[Archived Post] Panelists at George Mason’s IP conference debate litigation funding

Posted on: November 19, 2024May 13, 2026Conferences , Innovation , Inventors , Patent Law , Patents

By Kristen Osenga I recently had the pleasure of participating in a panel on third-party litigation funding (TPLF), which was part of the Annual Fall Conference at George Mason University’s […]

[Archived Post] What the FTC Gets Wrong About the FDA’s Orange Book

Posted on: November 18, 2024May 13, 2026Biotech , Healthcare , Innovation , Patent Law , Patents , Pharma

By Emily Michiko Morris & Douglas Park The high cost of some pharmaceuticals is a complex issue, but the Federal Trade Commission’s (FTC’s) most recent criticism of pharmaceutical patents’ role […]

[Archived Post] C-IP2 Celebrates the Release of Book 5G and Beyond: Intellectual Property and Competition Policy in the Internet of Things[1]

Posted on: April 29, 2024May 13, 2026C-IP2 News , High Tech Industry , Innovation , Internet , Patent Law , Patents , Software Patent

The following post comes from Jack Ring, a 3L at Scalia Law and a Research Assistant at C-IP2.  On April 15, 2024, C-IP2 scholars and contributors to 5G and Beyond: […]

[Archived Post] Professor Tabrez Ebrahim on Clean and Sustainable Technological Innovation

Posted on: March 25, 2021May 13, 2026Innovation , Patents

The following post comes from Associate Professor of Law Tabrez Ebrahim of California Western School of Law in San Diego, California. By Tabrez Ebrahim What role should patent law have […]

[Archived Post] Jonathan Barnett on the “License as Tax” Fallacy and the Real-World Benefits of Licensing

Posted on: August 18, 2020May 13, 2026Antitrust , Innovation , Patent Licensing

The following post comes from David Ward, a rising 2L at Scalia Law and a Research Assistant at CPIP. By David Ward “Casual metaphors can have dangerous consequences.” CPIP Senior […]

Posts pagination

Page 1 Page 2 … Page 12 Next page

Recent Posts

  • Domestic Manufacturing as a Discretionary Consideration: Domestic Industry at the PTAB?
  • If AI Can Pirate the Internet, Why Can’t You?
  • Most-Favored-Nation (MFN) Drug Pricing: You Can’t Import European Prices Without Importing European Tradeoffs
  • IPPI 2026 Spring Progress Report
  • IPPI 2025 Winter Progress Report

Archives

Theme Alaska Blog by Kantipur Themes